Literature DB >> 26655999

Targeting SDF-1 in multiple myeloma tumor microenvironment.

Juliette M C Bouyssou1, Irene M Ghobrial2, Aldo M Roccaro3.   

Abstract

Multiple myeloma (MM) is a type of B-cell malignancy that remains incurable to date. The bone marrow (BM) microenvironment plays a crucial role in MM progression. The chemokine SDF-1 (CXCL12) is an important actor of the BM microenvironment that has the ability to regulate numerous processes related to its malignant transformation during MM development. The activity of SDF-1 is mainly mediated by its specific receptor CXCR4, which is expressed at the surface of MM cells and various other BM cell types. Current treatments available for MM patients mainly target tumor cells but have limited effects on the BM microenvironment. In this context, SDF-1 and CXCR4 represent ideal targets for the normalization of the MM-supportive BM microenvironment. The present review focuses on the activity of SDF-1 in the MM BM microenvironment and the current efforts carried out to target the SDF-1/CXCR4 axis for treatment of MM.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bone marrow; CXCR4; Microenvironment; Multiple myeloma; SDF-1

Mesh:

Substances:

Year:  2015        PMID: 26655999     DOI: 10.1016/j.canlet.2015.11.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor.

Authors:  Jonathan N Hofmann; Ola Landgren; Rebecca Landy; Troy J Kemp; Loredana Santo; Charlene M McShane; Joseph J Shearer; Qing Lan; Nathaniel Rothman; Ligia A Pinto; Ruth M Pfeiffer; Allan Hildesheim; Hormuzd A Katki; Mark P Purdue
Journal:  JNCI Cancer Spectr       Date:  2019-12-16

2.  Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.

Authors:  H Ludwig; K Weisel; M T Petrucci; X Leleu; A M Cafro; L Garderet; C Leitgeb; R Foa; R Greil; I Yakoub-Agha; D Zboralski; S Vauléon; T Dümmler; D Beyer; A Kruschinski; K Riecke; M Baumann; M Engelhardt
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

3.  Clinicopathologic Significance of CXCL12 and CXCR4 Expressions in Patients with Colorectal Cancer.

Authors:  Naomi Yoshuantari; Didik Setyo Heriyanto; Susanna Hilda Hutajulu; Johan Kurnianda; Ahmad Ghozali
Journal:  Gastroenterol Res Pract       Date:  2018-05-16       Impact factor: 2.260

Review 4.  NF-κB, the Importance of Being Dynamic: Role and Insights in Cancer.

Authors:  Federica Colombo; Samuel Zambrano; Alessandra Agresti
Journal:  Biomedicines       Date:  2018-04-17

Review 5.  Molecular Players in Hematologic Tumor Cell Trafficking.

Authors:  Javier Redondo-Muñoz; Angeles García-Pardo; Joaquin Teixidó
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

6.  Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model.

Authors:  Alessandro Natoni; Mariah L Farrell; Sophie Harris; Carolyne Falank; Lucy Kirkham-McCarthy; Matthew S Macauley; Michaela R Reagan; Michael O'Dwyer
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

7.  Multiple Myeloma-Derived Extracellular Vesicles Impair Normal Hematopoiesis by Acting on Hematopoietic Stem and Progenitor Cells.

Authors:  Ilaria Laurenzana; Stefania Trino; Daniela Lamorte; Angelo De Stradis; Michele Santodirocco; Alessandro Sgambato; Luciana De Luca; Antonella Caivano
Journal:  Front Med (Lausanne)       Date:  2021-12-16

Review 8.  Metabolic Disorders in Multiple Myeloma.

Authors:  Maria Gavriatopoulou; Stavroula A Paschou; Ioannis Ntanasis-Stathopoulos; Meletios A Dimopoulos
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

9.  CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment.

Authors:  Cesarina Giallongo; Ilaria Dulcamare; Francesco Di Raimondo; Giuseppe A Palumbo; Daniele Tibullo; Vittorio Del Fabro; Nunzio Vicario; Nunziatina Parrinello; Alessandra Romano; Grazia Scandura; Giacomo Lazzarino; Concetta Conticello; Giovanni Li Volti; Angela Maria Amorini; Giuseppe Musumeci; Michelino Di Rosa; Francesca Polito; Rosaria Oteri; M'hammed Aguennouz; Rosalba Parenti
Journal:  Oncogenesis       Date:  2022-01-21       Impact factor: 7.485

Review 10.  Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases.

Authors:  Maher M Aljohani; Dana Cialla-May; Jürgen Popp; Raja Chinnappan; Khaled Al-Kattan; Mohammed Zourob
Journal:  Molecules       Date:  2022-01-07       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.